Stockscreener 앱 받기
3.61
1.63%
-0.06
시간 외 거래:
3.61
Proqr Therapeutics N V 주식(PRQR)의 최신 뉴스
RNA Editing Market Top Companies StudyProQR Therapeutics NV, - openPR
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving AverageTime to Sell? - MarketBeat
ProQR Therapeutics NV (MEX:PRQR) 50-Day SMA : MXN35.82 (As of Nov. 20, 2024) - GuruFocus.com
ProQR Therapeutics NV (FRA:0PQ) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
ProQR Therapeutics NV (FRA:0PQ) 3-Year EBITDA Growth Rate : 31.80% (As of Sep. 2024) - GuruFocus.com
ProQR Therapeutics NV (FRA:0PQ) 3-Year Book Growth Rate : -26.20% (As of Sep. 2024) - GuruFocus.com
ProQR Therapeutics NV (MEX:PRQR) Cash Flow from Financing : MXN-38.6 Mil (TTM As of Jun. 2024) - GuruFocus.com
Chardan Capital Issues Pessimistic Outlook for PRQR Earnings - Defense World
What is Chardan Capital's Forecast for PRQR FY2024 Earnings? - MarketBeat
ProQR: Q3 Earnings Snapshot - San Francisco Chronicle
ProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $10.00 at HC Wainwright - MarketBeat
ProQR Therapeutics NV earnings beat, revenue fell short of estimates - Investing.com
ProQR Therapeutics NV earnings beat, revenue fell short of estimates By Investing.com - Investing.com UK
PRQRProQR Therapeutics N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
ProQR Announces Third Quarter 2024 Operating and Financial Results - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Raymond James Upgrades ProQR Therapeutics N.V. (PRQR) - MSN
ProQR Therapeutics upgraded by Raymond James with a new price target - Quantisnow
ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Strong-Buy at Raymond James - MarketBeat
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement - GlobeNewswire
ProQR Announces Major Share Offering Agreement - TipRanks
There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump - Simply Wall St
ProQR Therapeutics drops on $75 mln equity raise as Eli Lilly pitches in - XM
Form 424B5 ProQR Therapeutics N.V. - StreetInsider.com
ProQR launches public offering to fund RNA therapy research - Investing.com India
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement - StockTitan
ProQR Therapeutics announces public offering of ordinary shares - MSN
ProQR launches public offering to fund RNA therapy research By Investing.com - Investing.com UK
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) shareholder returns have been solid, earning 231% in 1 year - Yahoo Finance
RNA-Editing Stocks Soar by Record on Wave Life’s Trial Data - Yahoo Finance
Proqr Therapeutics RNA editing technology counteracts cholestatic disease - BioWorld Online
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - The Manila Times
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - GlobeNewswire Inc.
ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving Average – Here’s Why - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving AverageHere's Why - MarketBeat
Investing in ProQR Therapeutics N.V (PRQR) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Best Momentum Stocks to Buy for October 2nd - Yahoo Finance
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase - Investing.com India
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase By Investing.com - Investing.com South Africa
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $1.95 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below Two Hundred Day Moving Average of $1.95 - Defense World
ProQR Therapeutics N.V (PRQR) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Market Momentum: ProQR Therapeutics N.V (PRQR) Registers a 7.14 Increase, Closing at 1.80 - The Dwinnex
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Below Two Hundred Day Moving Average of $1.96 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Below Two Hundred Day Moving Average of $1.96 - Defense World
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Above 50-Day Moving Average of $1.90 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50-Day Moving Average of $1.90 - Defense World
0.93%
3.55%
자본화:
|
볼륨(24시간):